The Vanguard Group 13D and 13G filings for Coherus BioSciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | Coherus BioSciences, Inc. CHRS |
The Vanguard Group | 10,357,412 9.300% |
4,541,530 (+78.09%) |
Filing |
| 2023-02-09 11:15 am Purchase |
2022-12-30 | 13G | Coherus BioSciences, Inc. CHRS |
The Vanguard Group | 5,815,882 7.480% |
1,268,353 (+27.89%) |
Filing |
| 2022-02-09 3:43 pm Purchase |
2021-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
The Vanguard Group | 4,547,529 5.920% |
418,594 (+10.14%) |
Filing |
| 2021-02-10 10:46 am Purchase |
2020-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
The Vanguard Group | 4,128,935 5.730% |
4,128,935 (New Position) |
Filing |